Literature DB >> 6092901

Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.

A C Howlett, R M Fleming.   

Abstract

Adenylate cyclase in plasma membranes was inhibited by micromolar concentrations of delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol and by levonantradol and desacetyllevonantradol. This inhibition was noncompetitive for stimulation of the enzyme at the prostanoid receptor by prostaglandin E1 or prostacyclin, or at the peptide receptor by secretin or vasoactive intestinal peptide. Forskolin-activated adenylate cyclase was also inhibited by cannabimimetic agents. Inhibition by cannabinoid compounds was neither synergistic nor additive with muscarinic or alpha-adrenergic agents when each was present at maximally inhibitory concentrations. Cannabinoid inhibition was not blocked by atropine, yohimbine, or naloxone, suggesting that muscarinic, alpha 2-adrenergic and certain opiate receptors may not be required for the response. The inhibition of adenylate cyclase was specific for psychoactive cannabinoids, since cannabinol and cannabidiol produced minimal or no response. Inhibition was also stereoselective, since dextronantradol did not produce the response. A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM. Possible mechanisms for the effects of cannabinoid drugs on adenylate cyclase activity are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092901

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  69 in total

1.  Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration.

Authors:  J Nie; D L Lewis
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

2.  Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells.

Authors:  George D Dalton; Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

4.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

5.  Interaction of delta-9-tetrahydrocannabinol with rat B103 neuroblastoma cells.

Authors:  G A Cabral; P J McNerney; E M Mishkin
Journal:  Arch Toxicol       Date:  1987-08       Impact factor: 5.153

6.  Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Authors:  Alexander F Hoffman; Murat Oz; Ruiqin Yang; Aron H Lichtman; Carl R Lupica
Journal:  Learn Mem       Date:  2007-01-03       Impact factor: 2.460

7.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

Review 8.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

9.  Cannabinoid ligand-receptor signaling in the mouse uterus.

Authors:  S K Das; B C Paria; I Chakraborty; S K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  The effect of anandamide on prolactin secretion is modulated by estrogen.

Authors:  Camila Scorticati; Claudia Mohn; Andrea De Laurentiis; Paula Vissio; Javier Fernández Solari; Adriana Seilicovich; Samuel M McCann; Valeria Rettori
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.